Prelude Therapeutics INC Form 4 insider transactions

CEO Krishna Vaddi reports purchasing shares of Prelude Therapeutics in multiple transactions.

Bryant David Lim, CLO, CFO, and Corporate Secretary of Prelude Therapeutics, was granted stock options for 200,000 shares on February 4, 2025.

Peggy Scherle, Chief Scientific Officer of Prelude Therapeutics Inc., was granted stock options for 175,000 shares on February 4, 2025.

Andrew Combs, Chief Chemistry Officer of Prelude Therapeutics Inc., acquired 175,000 employee stock options on February 4, 2025.

Jane Huang, President and CMO of Prelude Therapeutics, was granted stock options for 200,000 shares on February 4, 2025.

Krishna Vaddi, CEO of Prelude Therapeutics, was granted stock options for 496,000 shares on February 4, 2025, vesting over a period of four years.

Jane Huang, President and CMO of Prelude Therapeutics, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Prelude Therapeutics CEO, Krishna Vaddi, purchased 5,000 shares of common stock at $1.2087 per share on December 31, 2024.

Prelude Therapeutics CEO Krishna Vaddi reports the acquisition of 10,000 shares of common stock at $1.20 per share on December 30, 2024.

Andrew Combs, Chief Chemistry Officer of Prelude Therapeutics, recently acquired additional shares of the company's common stock through market purchases and the Employee Stock Purchase Plan.

A Prelude Therapeutics executive, Bryant David Lim, purchased 25,000 shares of common stock at a weighted average price of $0.9055 per share.

Prelude Therapeutics CEO, Krishna Vaddi, has acquired 100,000 shares of common stock at an average price of $0.9321 and 6,888 shares at $0.8879 in recent open market transactions.

Jane Huang, President and CMO of Prelude Therapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Jane Huang, President and CMO of Prelude Therapeutics, exercised stock options and disposed of shares to cover tax obligations on July 4, 2024.

Baker Bros. Advisors LP, along with related entities and individuals, reports the acquisition of non-qualified stock options in Prelude Therapeutics Inc. by Julian C. Baker, a director of the company.

Director Victor Sandor acquired 23,500 stock options in Prelude Therapeutics on June 14, 2024, according to a Form 4 filing.

Director Paul Friedman acquired 23,500 stock options in Prelude Therapeutics on June 14, 2024.

Director Dier Mardi acquired 23,500 stock options in Prelude Therapeutics on June 14, 2024.

Director David P. Bonita acquired stock options in Prelude Therapeutics, with potential transfer obligations to OrbiMed Private Investments VI, LP.

Director Martin Babler acquired 23,500 stock options in Prelude Therapeutics on June 14, 2024.

Bryant David Lim, CLO, Interim CFO, and Corporate Secretary of Prelude Therapeutics, was granted stock options for 25,000 shares on May 14, 2024.

Jane Huang, President and CMO of Prelude Therapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Bryant David Lim, Chief Legal Officer and Corporate Secretary of Prelude Therapeutics Inc., was granted stock options for 150,000 shares on March 1, 2024.

Peggy Scherle, Chief Scientific Officer of Prelude Therapeutics Inc., was granted stock options for 150,000 shares on March 1, 2024.

Andrew Combs, Chief Chemistry Officer of Prelude Therapeutics Inc., acquired 150,000 employee stock options on March 1, 2024, at an exercise price of $4.59.

Laurent Chardonnet, CFO of Prelude Therapeutics, was granted stock options for 150,000 shares on March 1, 2024.

Jane Huang, President and CMO of Prelude Therapeutics Inc., acquired 175,000 employee stock options on March 1, 2024.

Prelude Therapeutics CEO, Krishna Vaddi, was granted stock options to purchase 425,000 shares of common stock on March 1, 2024.